Wyeth mulls global sales force restructuring

Share this article:
Wyeth said the restructuring of its U.S. sales force was only a start and that it is considering making similar changes globally.
"Obviously it is a first step. We're also looking internationally. Our European affiliates have started to look at how to optimize the sales force," said Bernard Poussot, head of Wyeth's pharmaceutical operations said in a Financial Times report.
Last month, Wyeth said it would use inside, part-time sales representatives in the U.S. to complement its full-time sales force, which is being reduced by about 25 percent to 30 percent.
Adding the part-timers will result in a net sales force reduction of about 15 percent, Poussot said.
Wyeth has deployed part-timers in its consumer division for the past few years.
As reported in MM&M, the drug maker began piloting them in its pharmaceuticals division in July and said it will fully implement them by year's end (MM&M, July 2005).
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.